[1] Xu LJ, Lu F, Wei SC, et al. Comparative study of 8-hydroxydihydroberberine and berberine hydrochloride in the treatment of type 2 diabetes mellitus in rats[J]. Journal of Integrative Medicine, 2009, 1(04): 173-176.

[2] Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action[J]. Diabetes, 2008, 57(5): 1414-8.

[3] Dai B, Ma Y, Wang W, et al. Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI-H460 cells by repressing MAP kinase pathways and inflammatory mediators[J]. J Cell Mol Med, 2017, 21(10): 2573-2585.

[4] Li C, Dong N, Wu B, et al. Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice[J]. Phytomedicine, 2021, 90: 153631.

[5] Chen J, Cao J, Fang L, et al. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice[J]. J Transl Med, 2014, 12: 326.

[6] Xu L, Lin G, Yu Q, et al. Anti-Hyperuricemic and Nephroprotective Effects of Dihydroberberine in Potassium Oxonate- and Hypoxanthine-Induced Hyperuricemic Mice[J]. Front Pharmacol, 2021, 12: 645879.